Loading…

The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model

Asthma is an inflammatory disease caused by an imbalance of Th1 and Th2 cells. In general, asthma is characterized by a stronger Th2 response. Most conventional asthma treatment focuses on improving airway flow or suppression of airway inflammation. To reduce the side effects of currently used asthm...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2018-12, Vol.19 (12), p.4013
Main Authors: Hwang, Yun-Ho, Kim, Su-Jin, Kim, Hangun, Yee, Sung-Tae
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33
cites cdi_FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33
container_end_page
container_issue 12
container_start_page 4013
container_title International journal of molecular sciences
container_volume 19
creator Hwang, Yun-Ho
Kim, Su-Jin
Kim, Hangun
Yee, Sung-Tae
description Asthma is an inflammatory disease caused by an imbalance of Th1 and Th2 cells. In general, asthma is characterized by a stronger Th2 response. Most conventional asthma treatment focuses on improving airway flow or suppression of airway inflammation. To reduce the side effects of currently used asthma medicines, we have conducted studies on natural products that have no side effects. 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (TSG), the main compound of (PM), has various biological activities, including anti-inflammation and anti-oxidation activities. However, the effect of TSG on asthma has not been studied yet. We examined the effects of TSG on Th2 immune responses using an OVA-induced asthma animal model. OVA-sensitized mice were treated with TSG. 24 h after the last intranasal challenge, airway hyperresponsiveness (AHR) was measured or serum and bronchoalveolar lavage fluid (BALF) were harvested. We measured typical Th1 and Th2 cytokines in serum and BALF. As a result, TSG suppressed Th2 responses, as shown by the lower levels of IL-4, IL-5, total IgE, OVA-specific IgE, and OVA-specific IgG1. On the other hand, TSG increased Th1 responses, as shown by the levels of IFN-gamma. Collectively, these results confirm the potential of TSG for asthma treatment through modulation of inflammatory responses. Considering that the cytotoxic effect of PM extract is due to the cis isomer of TSG, if the effect of TSG on asthma treatment is found to be non-toxic in clinical trials, it would be more effective to use it as a purified component than PM extract as an asthma treatment agent.
doi_str_mv 10.3390/ijms19124013
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6321435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2582849026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33</originalsourceid><addsrcrecordid>eNpdkU9P3DAQxS0EAkq5ca4scWgPa2rPxMnupdIKUYoEWg7bXq3EnnS9SmKwE8R-LT5IP1OD-KNtT_Ok-enNPD3GTpQ8Q5zJr37dJjVTkEmFO-xQZQBCyrzY3dIH7ENKaykBQc_22QFKnWkF-SG7X66I38bQk-39A_GLuh5V4qHmMMGJnmSfxZL6WK42LobHTep9U1FHAgRfcPHnSThx2Qw2JO-I-473o9_i11xcdW6w5Pg89au25DfeEr8JjpqPbK8um0THr_OI_fx-sTz_Ia4Xl1fn82thMwW90ATaOagyWblaoZVKAUos0ILKsZBARFLVrtI4lUqWxRRcaV3hINcFOsQj9u3F926oWnKWujFFY-6ib8u4MaH05t9N51fmd3gwOYLKUI8GX14NYrgfKPWm9clS05QdhSEZULrIixzw-dbpf-g6DLEb4xnQU5hmMwn5SE1eKBtDSpHq92eUNM9dmu0uR_zTdoB3-K08_AtJKph5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582849026</pqid></control><display><type>article</type><title>The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Hwang, Yun-Ho ; Kim, Su-Jin ; Kim, Hangun ; Yee, Sung-Tae</creator><creatorcontrib>Hwang, Yun-Ho ; Kim, Su-Jin ; Kim, Hangun ; Yee, Sung-Tae</creatorcontrib><description>Asthma is an inflammatory disease caused by an imbalance of Th1 and Th2 cells. In general, asthma is characterized by a stronger Th2 response. Most conventional asthma treatment focuses on improving airway flow or suppression of airway inflammation. To reduce the side effects of currently used asthma medicines, we have conducted studies on natural products that have no side effects. 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (TSG), the main compound of (PM), has various biological activities, including anti-inflammation and anti-oxidation activities. However, the effect of TSG on asthma has not been studied yet. We examined the effects of TSG on Th2 immune responses using an OVA-induced asthma animal model. OVA-sensitized mice were treated with TSG. 24 h after the last intranasal challenge, airway hyperresponsiveness (AHR) was measured or serum and bronchoalveolar lavage fluid (BALF) were harvested. We measured typical Th1 and Th2 cytokines in serum and BALF. As a result, TSG suppressed Th2 responses, as shown by the lower levels of IL-4, IL-5, total IgE, OVA-specific IgE, and OVA-specific IgG1. On the other hand, TSG increased Th1 responses, as shown by the levels of IFN-gamma. Collectively, these results confirm the potential of TSG for asthma treatment through modulation of inflammatory responses. Considering that the cytotoxic effect of PM extract is due to the cis isomer of TSG, if the effect of TSG on asthma treatment is found to be non-toxic in clinical trials, it would be more effective to use it as a purified component than PM extract as an asthma treatment agent.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms19124013</identifier><identifier>PMID: 30545126</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Airway management ; Animal models ; Asthma ; Blood ; Bronchus ; Clinical trials ; Cytokines ; Cytotoxicity ; Glucosides ; Health services ; Helper cells ; Immune response ; Immunoglobulin E ; Immunoglobulin G ; Immunoglobulins ; Inflammatory diseases ; Interleukin 4 ; Interleukin 5 ; Liver ; Lungs ; Lymphocytes T ; Natural products ; Osteoporosis ; Oxidation ; Respiratory tract ; Respiratory tract diseases ; Side effects ; Steroids ; γ-Interferon</subject><ispartof>International journal of molecular sciences, 2018-12, Vol.19 (12), p.4013</ispartof><rights>2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 by the authors. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33</citedby><cites>FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2582849026/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2582849026?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30545126$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hwang, Yun-Ho</creatorcontrib><creatorcontrib>Kim, Su-Jin</creatorcontrib><creatorcontrib>Kim, Hangun</creatorcontrib><creatorcontrib>Yee, Sung-Tae</creatorcontrib><title>The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Asthma is an inflammatory disease caused by an imbalance of Th1 and Th2 cells. In general, asthma is characterized by a stronger Th2 response. Most conventional asthma treatment focuses on improving airway flow or suppression of airway inflammation. To reduce the side effects of currently used asthma medicines, we have conducted studies on natural products that have no side effects. 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (TSG), the main compound of (PM), has various biological activities, including anti-inflammation and anti-oxidation activities. However, the effect of TSG on asthma has not been studied yet. We examined the effects of TSG on Th2 immune responses using an OVA-induced asthma animal model. OVA-sensitized mice were treated with TSG. 24 h after the last intranasal challenge, airway hyperresponsiveness (AHR) was measured or serum and bronchoalveolar lavage fluid (BALF) were harvested. We measured typical Th1 and Th2 cytokines in serum and BALF. As a result, TSG suppressed Th2 responses, as shown by the lower levels of IL-4, IL-5, total IgE, OVA-specific IgE, and OVA-specific IgG1. On the other hand, TSG increased Th1 responses, as shown by the levels of IFN-gamma. Collectively, these results confirm the potential of TSG for asthma treatment through modulation of inflammatory responses. Considering that the cytotoxic effect of PM extract is due to the cis isomer of TSG, if the effect of TSG on asthma treatment is found to be non-toxic in clinical trials, it would be more effective to use it as a purified component than PM extract as an asthma treatment agent.</description><subject>Airway management</subject><subject>Animal models</subject><subject>Asthma</subject><subject>Blood</subject><subject>Bronchus</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Glucosides</subject><subject>Health services</subject><subject>Helper cells</subject><subject>Immune response</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Inflammatory diseases</subject><subject>Interleukin 4</subject><subject>Interleukin 5</subject><subject>Liver</subject><subject>Lungs</subject><subject>Lymphocytes T</subject><subject>Natural products</subject><subject>Osteoporosis</subject><subject>Oxidation</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Side effects</subject><subject>Steroids</subject><subject>γ-Interferon</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU9P3DAQxS0EAkq5ca4scWgPa2rPxMnupdIKUYoEWg7bXq3EnnS9SmKwE8R-LT5IP1OD-KNtT_Ok-enNPD3GTpQ8Q5zJr37dJjVTkEmFO-xQZQBCyrzY3dIH7ENKaykBQc_22QFKnWkF-SG7X66I38bQk-39A_GLuh5V4qHmMMGJnmSfxZL6WK42LobHTep9U1FHAgRfcPHnSThx2Qw2JO-I-473o9_i11xcdW6w5Pg89au25DfeEr8JjpqPbK8um0THr_OI_fx-sTz_Ia4Xl1fn82thMwW90ATaOagyWblaoZVKAUos0ILKsZBARFLVrtI4lUqWxRRcaV3hINcFOsQj9u3F926oWnKWujFFY-6ib8u4MaH05t9N51fmd3gwOYLKUI8GX14NYrgfKPWm9clS05QdhSEZULrIixzw-dbpf-g6DLEb4xnQU5hmMwn5SE1eKBtDSpHq92eUNM9dmu0uR_zTdoB3-K08_AtJKph5</recordid><startdate>20181212</startdate><enddate>20181212</enddate><creator>Hwang, Yun-Ho</creator><creator>Kim, Su-Jin</creator><creator>Kim, Hangun</creator><creator>Yee, Sung-Tae</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181212</creationdate><title>The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model</title><author>Hwang, Yun-Ho ; Kim, Su-Jin ; Kim, Hangun ; Yee, Sung-Tae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Airway management</topic><topic>Animal models</topic><topic>Asthma</topic><topic>Blood</topic><topic>Bronchus</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Glucosides</topic><topic>Health services</topic><topic>Helper cells</topic><topic>Immune response</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Inflammatory diseases</topic><topic>Interleukin 4</topic><topic>Interleukin 5</topic><topic>Liver</topic><topic>Lungs</topic><topic>Lymphocytes T</topic><topic>Natural products</topic><topic>Osteoporosis</topic><topic>Oxidation</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Side effects</topic><topic>Steroids</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hwang, Yun-Ho</creatorcontrib><creatorcontrib>Kim, Su-Jin</creatorcontrib><creatorcontrib>Kim, Hangun</creatorcontrib><creatorcontrib>Yee, Sung-Tae</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hwang, Yun-Ho</au><au>Kim, Su-Jin</au><au>Kim, Hangun</au><au>Yee, Sung-Tae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2018-12-12</date><risdate>2018</risdate><volume>19</volume><issue>12</issue><spage>4013</spage><pages>4013-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Asthma is an inflammatory disease caused by an imbalance of Th1 and Th2 cells. In general, asthma is characterized by a stronger Th2 response. Most conventional asthma treatment focuses on improving airway flow or suppression of airway inflammation. To reduce the side effects of currently used asthma medicines, we have conducted studies on natural products that have no side effects. 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (TSG), the main compound of (PM), has various biological activities, including anti-inflammation and anti-oxidation activities. However, the effect of TSG on asthma has not been studied yet. We examined the effects of TSG on Th2 immune responses using an OVA-induced asthma animal model. OVA-sensitized mice were treated with TSG. 24 h after the last intranasal challenge, airway hyperresponsiveness (AHR) was measured or serum and bronchoalveolar lavage fluid (BALF) were harvested. We measured typical Th1 and Th2 cytokines in serum and BALF. As a result, TSG suppressed Th2 responses, as shown by the lower levels of IL-4, IL-5, total IgE, OVA-specific IgE, and OVA-specific IgG1. On the other hand, TSG increased Th1 responses, as shown by the levels of IFN-gamma. Collectively, these results confirm the potential of TSG for asthma treatment through modulation of inflammatory responses. Considering that the cytotoxic effect of PM extract is due to the cis isomer of TSG, if the effect of TSG on asthma treatment is found to be non-toxic in clinical trials, it would be more effective to use it as a purified component than PM extract as an asthma treatment agent.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30545126</pmid><doi>10.3390/ijms19124013</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2018-12, Vol.19 (12), p.4013
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6321435
source Publicly Available Content Database; PubMed Central
subjects Airway management
Animal models
Asthma
Blood
Bronchus
Clinical trials
Cytokines
Cytotoxicity
Glucosides
Health services
Helper cells
Immune response
Immunoglobulin E
Immunoglobulin G
Immunoglobulins
Inflammatory diseases
Interleukin 4
Interleukin 5
Liver
Lungs
Lymphocytes T
Natural products
Osteoporosis
Oxidation
Respiratory tract
Respiratory tract diseases
Side effects
Steroids
γ-Interferon
title The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2- O -β-d-Glucoside in the OVA-Induced Asthma Mice Model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A58%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Protective%20Effects%20of%202,3,5,4'-Tetrahydroxystilbene-2-%20O%20-%CE%B2-d-Glucoside%20in%20the%20OVA-Induced%20Asthma%20Mice%20Model&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Hwang,%20Yun-Ho&rft.date=2018-12-12&rft.volume=19&rft.issue=12&rft.spage=4013&rft.pages=4013-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms19124013&rft_dat=%3Cproquest_pubme%3E2582849026%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-5e25dd2b40bdf13c011230373c2163702eee01fdb538010a782dacd7d26573d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2582849026&rft_id=info:pmid/30545126&rfr_iscdi=true